Narcotic Treatment Programs (NTP) Q&A
Question: How can a Narcotic Treatment Program provide Food and Drug Administration approved narcotic controlled substances (e.g. methadone/buprenorphine) used in opioid use disorder maintenance and detoxification treatment to an unregistered off-site location such as a correctional facility, long-term care facility, alcohol treatment center, behavioral health facility, or home-bound patient?
Answer: See the Narcotic Treatment Program Manual (revised 2022), pages 28-31. EO-DEA256, July 25, 2022
Disclaimer: Guidance documents, like this document, are not binding and lack the force and effect of law, unless expressly authorized by statute or expressly incorporated into a contract, grant, or cooperative agreement. Consistent with Executive Order 13891 and the Office of Management and Budget implementing memoranda, the Department will not cite, use, or rely on any guidance document that is not accessible through the Department's guidance portal, or similar guidance portals for other Executive Branch departments and agencies, except to establish historical facts. To the extent any guidance document sets out voluntary standards (e.g., recommended practices), compliance with those standards is voluntary, and noncompliance will not result in enforcement action. Guidance documents may be rescinded or modified in the Department's complete discretion, consistent with applicable laws.